Conference webcast

http://www.wsw.com/webcast/roth29/bota/

Patti discusses where things are at in terms of their various trials.

He discusses LANI and the upcoming discussions with the FDA.  He discusses how good the last trial was, given the mild flu season, but not a single mention of BARDA (I guess that is history).

He discusses royalties and also mentions the present patent pending extension on Relenza in the US.  While that patent pending application continues, royalties will continue from GSK on US sales.  If the patent extends, I think he said this will add another 17 (?) years.

By second half of 2016, their RSV and HPV candidates are hoped to pass respective 2b trials - that will leave a number of bases loaded at 2b stage - I guess they will be hoping/expecting this to trigger some sort of a rerating.